Generic Name and Formulations:
Tiagabine HCl 2mg, 4mg, 12mg, 16mg; tabs.
Indications for GABITRIL:
Adjunct in partial seizures.
Take with food. Use lower doses and titrate slower if not on concomitant enzyme-inducing drug(s). 12–18yrs: 4mg once daily for 1 week; may increase to 8mg/day in 2 divided doses for 1 week; then may increase by 4–8mg weekly to clinical response or up to 32mg/day in 2–4 divided doses. ≥18yrs: 4mg once daily for 1 week; may increase by 4–8mg weekly to clinical response or up to 56mg/day in 2–4 divided doses.
Hepatic impairment: reduce dose. Reduce dose or discontinue if generalized weakness occurs. Adjust dose if spike and wave discharges on EEG with cognitive or neuropsychiatric events occur. Suicidal tendencies (monitor). Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
CNS depression potentiated by alcohol, triazolam, other CNS depressants. Tiagabine levels reduced by enzyme inducers (eg, phenytoin, carbamazepine, primidone, phenobarbital). May interact with valproate (monitor). May affect or be affected by highly protein bound drugs.
GABA reuptake inhibitor.
Dizziness, asthenia, somnolence, fatigue, GI upset/pain, nervousness, tremor, abdominal pain, concentration difficulties, dysphasia, confusion, other CNS effects, serious rash; possible long-term ophthalmologic effects.
- 16mg tablets (Qty:20)
- appx. price $245.00
- NSAIDs Linked to Long-Term Colon Cancer Risk Reduction
- Clinical Suspicion Leads to Uncommon Diagnosis in Patient With High Fever
- What a New Study Says About Omega-3s and Brain Health
- Too Much of This Mineral May Lead to Increased Appetite, Overeating
- New Insight into Antibiotics-Type 2 Diabetes Link
- Can Education Boost Adherence to Apixaban? New Data Presented
- Sensus Wearable Device for RLS: Pilot Study Data Announced
- Ezetimibe Add-On Tx Shows CV Benefits in Patients With Diabetes, ACS
- First State Adds Locking Devices to Rx Bottles for Deter Abuse, Misuse
- Osteonecrosis of Jaw Risk Highest for Two Bisphosphonates